Extensive ongoing research about the effects of obesity treatment, especially focused on GLP1-RAs, on occurrence and development of cancer have highlighted the increased potential for their use in the clinical setting of cancer treatment, first reducing obesity/ABCD and, second, influencing cancer cells by altering proliferation, apoptosis, extracellular matrix remodeling and the response to chemotherapy. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.